COURSE DESCRIPTION: 
Join us for Grand Rounds with Rogelio Mejia, M.D., as he explores the evolving landscape of Chagas disease diagnosis and post-treatment evaluation. This presentation will review the epidemiology of Trypanosoma cruzi infection, compare current diagnostic approaches for acute and chronic disease, and examine emerging serologic and molecular markers used to assess treatment response. Don't miss this opportunity to gain practical insights into a disease of growing clinical relevance across the Americas.

TARGET AUDIENCE:

Internal Medicine Physicians, Cardiologists, Pulmonologists, Oncologists, Pharmacists, Physician Assistants, Residents, Advanced Practice Registered Nurses, and all other interested healthcare providers

LEARNING OBJECTIVES:

• Describe the epidemiology and clinical significance of Chagas disease in the United States and throughout the Americas.
• Compare current diagnostic approaches for acute and chronic Trypanosoma cruzi infection, including their limitations.
• Evaluate available and emerging methods for assessing treatment response, including serologic and molecular markers.

FACULTY AND DISCLOSURES:

Rojelio Mejia, M.D 
Associate Professor
Department of Pediatrics, Division of Pediatric Tropical Medicine
Department of Medicine, Section of Infectious Diseases
Department of Molecular Virology & Microbiology
Director, Laboratory of Human and Environmental Parasitology
Division of Pediatric Tropical Medicine
Director, Molecular Parasitology Testing Unit
Texas Children's Hospital Center for Vaccine Development
Co-Editor in Chief, Current Tropical Medicine Reports,
Springer, US
Baylor College of Medicine
Houston, Texas

Rojelio Mejia, M.D., faculty for this educational activity, is a speaker for New England Biolabs. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.  All of the relevant financial relationships listed for these individuals have been mitigated.

John F. Rubin, M.D., FACP, director for this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships with ineligible companies* to disclose.

*Ineligible companies – Companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

ACCREDITATION STATEMENTS AND CREDITS

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.

Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

This activity has been approved for 1 credit hour, CE Broker Course #20-1296402, by the Florida Boards of Medicine, Podiatry, Osteopathic Medicine and Physician Assistants.  

This activity has also been approved for 1 credit for Nurse Practitioners, Nurses, Pharmacists and Pharmacy Techs, Laboratory Personnel, Athletic Trainers and Respiratory Techs. Baptist Health South Florida CE Broker Provider #50-182.